Is there a generic for Mometasone furoate?

Yes. The FDA Orange Book lists 25 approved generic (ANDA) applications for Mometasone furoate, referencing the brand NASONEX 24HR ALLERGY. Generics rated with an "A" therapeutic-equivalence code are considered substitutable for the brand.

What is the reference-listed drug for Mometasone furoate?

NASONEX 24HR ALLERGY (NDA 215712, PERRIGO PHARMA INTL) is the reference-listed drug, the approved product a generic applicant must show its version is the same as.

What patents protect Mometasone furoate?

The Orange Book lists 7 patents against Mometasone furoate products, with the earliest listed expiry in 2026. Listed patents cover the drug substance, drug product, or approved methods of use, and a generic launching before they expire must file a Paragraph IV certification.

What dosage forms of Mometasone furoate are approved?

Mometasone furoate is approved in the following dosage forms: aerosol, metered, cream, implant, lotion, ointment, powder, spray, metered.

FDA Orange Book · active-ingredient family

Mometasone furoate

Mometasone furoate: 8 brands, 25 generics; first approved Apr 30, 1987; generic available.

Generic availableHas discontinued products

Generic status & protection

Generic available: 25 ANDA applications approved.

Earliest patent expiry Apr 04, 2026

Brands (NDA)

Generics (ANDA)

Listed patents

Next patent expiry

Apr 04, 2026

6 mo ago

Brand (NDA) products

Originator applications

NASONEX 24HR ALLERGYRLDRS
PERRIGO PHARMA INTLNDA 2157122022
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.05MG/SPRAY SPRAY, METERED NASAL OTC —

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.05MG/SPRAY	SPRAY, METERED	NASAL	OTC	—

ASMANEX HFARLDRS

ORGANON LLCNDA 20564120193 strengths

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.10MG/INH	AEROSOL, METERED	INHALATION	Rx	—
0.20MG/INH	AEROSOL, METERED	INHALATION	Rx	—
0.05MG/INH	AEROSOL, METERED	INHALATION	Rx	—

SINUVARLDRS
INTERSECT ENT INCNDA 2093102017
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
1.35MG IMPLANT IMPLANTATION Rx —
ELOCONRLD
ORGANONNDA 01962520132 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% CREAM TOPICAL Discontinued —
0.1% CREAM TOPICAL Discontinued —
ASMANEX TWISTHALERRLDRS
ORGANON LLCNDA 02106720082 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.22MG/INH POWDER INHALATION Rx —
0.11MG/INH POWDER INHALATION Rx —
NASONEXRLD
ORGANON LLCNDA 0207621997
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.05MG/SPRAY SPRAY, METERED NASAL Discontinued —
ELOCONRLD
ORGANONNDA 0197961989
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% LOTION TOPICAL Discontinued —
ELOCONRLD
ORGANONNDA 0195431987
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% OINTMENT TOPICAL Discontinued —

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
1.35MG	IMPLANT	IMPLANTATION	Rx	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	CREAM	TOPICAL	Discontinued	—
0.1%	CREAM	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.22MG/INH	POWDER	INHALATION	Rx	—
0.11MG/INH	POWDER	INHALATION	Rx	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.05MG/SPRAY	SPRAY, METERED	NASAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	LOTION	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	OINTMENT	TOPICAL	Discontinued	—

Generic (ANDA) products (25)

Abbreviated applications

MOMETASONE FUROATE
NASPRESSANDA 2117062025
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.05MG/SPRAY SPRAY, METERED NASAL Rx AB
MOMETASONE FUROATE
AUROBINDO PHARMAANDA 2174982024
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.05MG/SPRAY SPRAY, METERED NASAL Discontinued —
MOMETASONE FUROATE
APOTEXANDA 2174382024
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.05MG/SPRAY SPRAY, METERED NASAL Discontinued —
MOMETASONE FUROATE
AUROBINDO PHARMAANDA 2158782024
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.05MG/SPRAY SPRAY, METERED NASAL Rx AB
MOMETASONE FUROATE
AMNEALANDA 2174602023
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.05MG/SPRAY SPRAY, METERED NASAL Discontinued —
MOMETASONE FUROATE
TORRENTANDA 2078992018
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% OINTMENT TOPICAL Rx AB
MOMETASONE FUROATE
AMNEAL PHARMSANDA 2079892017
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.05MG/SPRAY SPRAY, METERED NASAL Rx AB
MOMETASONE FUROATERS
APOTEXANDA 0911612016
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.05MG/SPRAY SPRAY, METERED NASAL Rx AB
MOMETASONE FUROATE
GLENMARK PHARMS LTDANDA 0905062010
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% LOTION TOPICAL Discontinued —
MOMETASONE FUROATE
GLENMARK PHARMSANDA 0785412008
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% CREAM TOPICAL Discontinued —
MOMETASONE FUROATE
GLENMARK PHARMSANDA 0785712008
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% OINTMENT TOPICAL Discontinued —
MOMETASONE FUROATE
FOUGERA PHARMSANDA 0759192007
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% LOTION TOPICAL Rx AB
MOMETASONE FUROATE
COSETTE PHARMS NCANDA 0776782007
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% LOTION TOPICAL Discontinued —
MOMETASONE FUROATE
ENCUBEANDA 0764992007
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% LOTION TOPICAL Rx AB
MOMETASONE FUROATE
CHARTWELL MOLECULARANDA 0765912007
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% CREAM TOPICAL Discontinued —
MOMETASONE FUROATE
COSETTE PHARMS NCANDA 0774012006
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% OINTMENT TOPICAL Rx AB
MOMETASONE FUROATERS
COSETTE PHARMS NCANDA 0774472006
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% CREAM TOPICAL Rx AB
MOMETASONE FUROATE
SUN PHARMA CANADAANDA 0767882006
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% LOTION TOPICAL Discontinued —
MOMETASONE FUROATE
FOUGERA PHARMSANDA 0761712005
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% CREAM TOPICAL Discontinued —
MOMETASONE FUROATERS
PADAGIS ISRAELANDA 0771802005
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% LOTION TOPICAL Rx AB
MOMETASONE FUROATE
FOUGERA PHARMSANDA 0770612005
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% OINTMENT TOPICAL Rx AB
MOMETASONE FUROATE
SUN PHARMA CANADAANDA 0766792004
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% CREAM TOPICAL Rx AB
MOMETASONE FUROATE
SUN PHARMA CANADAANDA 0766242004
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% OINTMENT TOPICAL Discontinued —
MOMETASONE FUROATE
ENCUBEANDA 0764812003
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% OINTMENT TOPICAL Rx AB
MOMETASONE FUROATERS
PADAGIS USANDA 0760672002
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
0.1% OINTMENT TOPICAL Rx AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.05MG/SPRAY	SPRAY, METERED	NASAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.05MG/SPRAY	SPRAY, METERED	NASAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.05MG/SPRAY	SPRAY, METERED	NASAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.05MG/SPRAY	SPRAY, METERED	NASAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.05MG/SPRAY	SPRAY, METERED	NASAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	OINTMENT	TOPICAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.05MG/SPRAY	SPRAY, METERED	NASAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.05MG/SPRAY	SPRAY, METERED	NASAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	LOTION	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	CREAM	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	OINTMENT	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	LOTION	TOPICAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	LOTION	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	LOTION	TOPICAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	CREAM	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	OINTMENT	TOPICAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	CREAM	TOPICAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	LOTION	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	CREAM	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	LOTION	TOPICAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	OINTMENT	TOPICAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	CREAM	TOPICAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	OINTMENT	TOPICAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	OINTMENT	TOPICAL	Rx	AB

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
0.1%	OINTMENT	TOPICAL	Rx	AB

Patent & exclusivity timeline

Protection horizon

Patent expiryExclusivity endToday

Listed patents

Orange Book patent file

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
Patent	Expires	In	Type
9585681	Apr 04, 2026	6 mo ago	U-2272
7544192	Nov 29, 2026	in 2 mo	U-2272
8025635	Jun 12, 2027	in 8 mo	ProductU-2272
10357640	Oct 03, 2031	in 5 yr 1 mo	U-2272
8763222	Feb 08, 2032	in 5 yr 5 mo	Product
10406332	Mar 13, 2034	in 7 yr 6 mo	Product
10232152	Nov 24, 2034	in 8 yr 3 mo	ProductU-2272

Approval history

FDA approval span

First approval

Apr 30, 1987

40 yr ago

Most recent approval

May 15, 2025

1 yr 5 mo ago

Approvals span 1987–2025 across 33 FDA applications.

Brand (NDA) 824%

Generic (ANDA) 2576%

Mometasone furoate: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo